Clinical Trial Registration of Xuefu Zhuyu Capsule
- Conditions
- Angina after PCI
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- Not specified
1. Aged 30-75 years;
2. Patients with angina pectoris symptoms within 12 months after PCI;
3. Patients with Qi stagnation and blood stasis syndrome based on TCM differentiation;
4. The patient signs an informed consent form, has good compliance, and cooperates with follow-up visits and re-examinations.
1. Diagnosed as STEMI, or diagnosed as NSTEMI who is at high risk by Grace score;
2. Patients with congenital heart disease, severe pulmonary hypertension, malignant tumors, severe COPD;
3. Valvular disease (LVEF < 30%), with cardiomyopathy, pericardial effusion, severe arrhythmia;
4. Before screening, any laboratory test index meets the following criteria: Admission liver and kidney function prompts: ALT, AST > 1.5 times the upper limit of normal value, Cr > 1.2 times the upper limit of normal value (refer to the laboratory test normal value of the research center Scope); Other clinically significant laboratory tests are abnormal and the investigator determines that it is not suitable to be included in the group;
5. People with allergies or allergies to the test drug Xuefu Zhuyu Capsules, excipients or similar ingredients;
6. Suspected or true history of alcohol or drug abuse;
7. Pregnant or breastfeeding women or those who have planned pregnancy in the near future and are unwilling to use contraceptive measures;
8. Patients who have participated in other clinical trials within 1 month before enrollment;
9. The investigator believes that it is not appropriate to participate in this clinical trial.
Study & Design
- Study Type
- Interventional study
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Reduction rate of nitroglycerin;
- Secondary Outcome Measures
Name Time Method Seattle Angina Scale;Angina pectoris symptom assessment;Traditional Chinese Medicine symptoms;Assessment of anxiety and depression status of patients after PCI;Angina pectoris efficacy evaluation;